SG11202010969UA - Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition - Google Patents
Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical compositionInfo
- Publication number
- SG11202010969UA SG11202010969UA SG11202010969UA SG11202010969UA SG11202010969UA SG 11202010969U A SG11202010969U A SG 11202010969UA SG 11202010969U A SG11202010969U A SG 11202010969UA SG 11202010969U A SG11202010969U A SG 11202010969UA SG 11202010969U A SG11202010969U A SG 11202010969UA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- addition salt
- crystal form
- receptor agonist
- agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/085617 WO2019210511A1 (en) | 2018-05-04 | 2018-05-04 | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010969UA true SG11202010969UA (en) | 2020-12-30 |
Family
ID=68387039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010969UA SG11202010969UA (en) | 2018-05-04 | 2018-05-04 | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11512078B2 (en) |
| EP (2) | EP4353719A1 (en) |
| JP (2) | JP7275253B2 (en) |
| KR (1) | KR20210019999A (en) |
| AU (1) | AU2018421487A1 (en) |
| BR (1) | BR112020022429A2 (en) |
| CA (1) | CA3099196A1 (en) |
| MX (1) | MX2020011665A (en) |
| SG (1) | SG11202010969UA (en) |
| WO (1) | WO2019210511A1 (en) |
| ZA (1) | ZA202007347B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3201000A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| EP4248883A1 (en) | 2020-11-18 | 2023-09-27 | Nomura Unison Co., Ltd. | Surgical instrument |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| CN103450171B (en) * | 2013-09-22 | 2015-07-08 | 苏州康乃德生物医药有限公司 | Novel immune adjustment compound, application thereof and medicine combination comprising same |
| CN105315266B (en) * | 2014-08-01 | 2019-10-01 | 苏州康乃德生物医药有限公司 | The crystal form of 1- { the fluoro- 4- of 2- [5- (4- isobutyl phenenyl) -1,2,4- oxadiazoles -3- base]-benzyl } -3- azetidinecarboxylic acid |
| CN105348276B (en) | 2014-08-22 | 2020-05-26 | 苏州康乃德生物医药有限公司 | Synthesis method of 1- { 2-fluoro-4- [5- (4-isobutylphenyl) -1,2, 4-oxadiazole-3-yl ] -benzyl } -3-azetidinecarboxylic acid |
| CN115772166A (en) | 2017-01-11 | 2023-03-10 | 苏州康乃德生物医药有限公司 | Addition salt of S1P1 receptor agonist, crystal form and pharmaceutical composition thereof |
-
2018
- 2018-05-04 CA CA3099196A patent/CA3099196A1/en active Pending
- 2018-05-04 EP EP24155906.1A patent/EP4353719A1/en active Pending
- 2018-05-04 SG SG11202010969UA patent/SG11202010969UA/en unknown
- 2018-05-04 AU AU2018421487A patent/AU2018421487A1/en active Pending
- 2018-05-04 JP JP2021510499A patent/JP7275253B2/en active Active
- 2018-05-04 KR KR1020207034174A patent/KR20210019999A/en active IP Right Grant
- 2018-05-04 BR BR112020022429-4A patent/BR112020022429A2/en unknown
- 2018-05-04 MX MX2020011665A patent/MX2020011665A/en unknown
- 2018-05-04 EP EP18917186.1A patent/EP3792258B1/en active Active
- 2018-05-04 WO PCT/CN2018/085617 patent/WO2019210511A1/en active Application Filing
- 2018-05-04 US US17/052,160 patent/US11512078B2/en active Active
-
2020
- 2020-11-25 ZA ZA2020/07347A patent/ZA202007347B/en unknown
-
2022
- 2022-10-06 US US17/961,270 patent/US20230050777A1/en active Pending
-
2023
- 2023-02-17 JP JP2023023091A patent/JP2023062091A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3099196A1 (en) | 2019-11-07 |
| JP2023062091A (en) | 2023-05-02 |
| EP4353719A1 (en) | 2024-04-17 |
| KR20210019999A (en) | 2021-02-23 |
| EP3792258A1 (en) | 2021-03-17 |
| EP3792258A4 (en) | 2021-10-06 |
| US11512078B2 (en) | 2022-11-29 |
| WO2019210511A1 (en) | 2019-11-07 |
| US20230050777A1 (en) | 2023-02-16 |
| AU2018421487A1 (en) | 2020-12-17 |
| BR112020022429A2 (en) | 2021-02-09 |
| US20210230152A1 (en) | 2021-07-29 |
| JP2021532165A (en) | 2021-11-25 |
| ZA202007347B (en) | 2021-10-27 |
| MX2020011665A (en) | 2021-01-20 |
| EP3792258B1 (en) | 2024-02-07 |
| JP7275253B2 (en) | 2023-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE052749T2 (en) | Pharmaceutical compositions comprising meloxicam and rizatriptan | |
| SG11202011883RA (en) | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof | |
| IL283362A (en) | Thrβ receptor agonist compound and preparation method and use thereof | |
| EP3572409A4 (en) | 1,3,5-triazine derivative salt, crystal, preparation method, pharmaceutical composition and use thereof | |
| IL289763A (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | |
| ZA201804387B (en) | Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide | |
| EP3825308A4 (en) | Compound, composition, and use thereof in preparation of drug | |
| ZA202007347B (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| EP3785713A4 (en) | Salt of cetagliptin, preparation method therefor, pharmaceutical composition, and use thereof | |
| EP3582759A4 (en) | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide | |
| EP3770148A4 (en) | Receptor inhibitor, pharmaceutical composition comprising same, and use thereof | |
| ZA202006157B (en) | Pharmaceutical composition of kor receptor agonist | |
| EP3650444B8 (en) | Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof | |
| SG11201605742TA (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
| EP3811941C0 (en) | Pharmaceutical composition containing ilaprazole and salt thereof and preparation method therefor | |
| EP3760620A4 (en) | Receptor antagonist, pharmaceutical composition comprising same, and usage thereof | |
| IL279202A (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
| EP3747866A4 (en) | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | |
| EP3889157C0 (en) | Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof | |
| EP3693374A4 (en) | Novel 2-carboxypenam compound or salt thereof, pharmaceutical composition containing said compound or salt, and application thereof | |
| EP3681492A4 (en) | Compounds, pharmaceutical compositions and use thereof as inhibitors of ran gtpase | |
| ZA201804996B (en) | Ophthalmic pharmaceutical composition containing brinzolamide and timolol and method for the preparation thereof | |
| EP3412291A4 (en) | Crystal form of imidazolone type compounds, and preparation method, pharmaceutical composition and use thereof | |
| PT3431106T (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |